Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks.

Click here to read the full articles:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext 

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext

Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering. 

Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin

Podcast editing: Matteo Simonetti

Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

Find the best science for better lives at www.thelancet.com

Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av, eller tillsammans med, Poddtoppen.